Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L. C., Haddad, R. I., Rordorf, T., Kiyota, N., Tahara, M., Lynch, M., Li, L., Gillison, M. ELSEVIER SCIENCE INC. 2018: 1317

View details for Web of Science ID 000428145600062